At our hospital, only generic drug names are displayed on the pharmacy labels.
We got a request to add Brand Name in addition to generic name in order to differentiate certain LASA meds.

For example:
Current state: duloxetine 30 mg capsule

Proposed change: duloxetine (Cymbalta) 30 mg capsule

Does your hospital have brand name as part of the drug name displayed on the pharmacy label?

My other concern is: if we affix a pharmacy label with brand name on a generic product, isn't this considered "misbranding"?

Thank you!

Our system is currently in the process of consolidating 11 individual Alaris pump libraries into 1 system library. We still have independent IV administration guidelines that dictate areas in the hospital that certain medications can be given and monitoring along with it.

Have any of you consolidated your IV administration guidelines as a system? What parameters did you use to broadly define areas within the IV administration guideline that can be expanded to other hospitals or in times of high census where patients are in hallways.

What weight do you typically utilize when calculating IVIG RATE for administration--actual or ideal? Can you please provide the rationale?

Best,
Stacie Ethington MSN, RN
Medication Safety Nurse Specialist
Nebraska Medicine

Hello All,

Based on ISMP best practice, patient weights should be documented in admission and during each appropriate outpatient or emergency encounter.

*Appropriate = encounter where patient being seen by licensed independent practitioner (excluding emergencies where delay may cause harm). Encounters that involved lab and other services where medications are not prescribed or administered would be considered an exclusion.

We have had 3 cases of cardiac arrest after a dose of ceftriaxone via IV push, one case in 2020, and two more cases recently. None of these cases had any other features of typical anaphylactic reactions (no hives, swelling, etc.).

Have any other sites experienced similar cases? If so, what were the details of the events? Do you believe the rate of IV push increases the risk of these reactions?

Any information would be much appreciated!

With the unavailability of Lorazepam 2mg/ml injectable solution, has anyone been diluting the 4mg/ml concentration to 2mg/ml? The stability data on this is not concise.

Does anyone have electronic or other tools in place to help prevent ADRs associated with morphine use in patients with severe renal dysfunction? I'm thinking maybe focused alerts for ER formulations, opioid-native patients, high doses, and/or patients who are receiving frequent prn doses?  There's no specific manufacturer recommendations, but Lexicomp provides some general guidance on dosing, etc.  

Thanks!

Our organization has moved to a new vendor and there are some opportunities for us to "fill the gap" based on what is available.

Specifically in the anticoagulation area.

Thanks

Hello-
We are working to implement a policy/procedure to outline the management of dual pharmacist order verification for select medications. We would greatly appreciate learning from others if anyone is willing to share their policy or processes. We are interested in your criteria for how a medication is determined to be added to the dual pharmacist order verification list, etc. Thank you!

Jennifer Noped

Since transitioning to outsourcing TPN, we are likely to have increased home TPN usage in the hospital for the first day of admission. Does your facility have nurses document home TPN administration on the MAR like a regular home medication? If so, how is it built out-- as a general "home TPN" order or as a specific TPN order broken down into components? Thanks! -Melody Sun, CHOC Children's